Table 2 Drugs used in the combination treatment of PD-1 inhibitors and antiangiogenic treatment
Agents of combination strategy | n (%) |
|---|---|
Camrelizumab + anlotinib | 46 (54.11) |
Camrelizumab + apatinib | 15 (17.65) |
Camrelizumab + bevacizumab | 5 (5.88) |
Sintilimab + anlotinib | 5 (5.88) |
Sintilimab + apatinib | 4 (4.71) |
Pembrolizumab + anlotinib | 4 (4.71) |
Pembrolizumab + apatinib | 2 (2.35) |
Toripalimab + anlotinib | 3 (3.53) |
Tislelizumab + anlotinib | 1 (1.18) |